Pharma BD Deal Intelligence
A small, unglamorous asset buy that quietly paid for itself many times over as a durable oncology cash-flow product
Full analysis, sources & comparables →The transaction was structured for '$70 million in cash, and possible future milestones of up to $100 million,' covering 'worldwide marketing, sales and…
Cell Therapeutics 'received about $29 million' from the initial sale, with cumulative Trisenox revenue of $81.3 million by Q3 2005; by 2003 'approximately…
Cephalon CEO Frank Baldino Jr. framed the deal as building 'a fully integrated oncology business' alongside TREANDA and CEP-701; under his leadership Cephalon…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cephalon acquires worldwide rights (ex-Asia) to TRISENOX (arsenic trioxide) from Cell Therapeutics. Oncology asset deal.
A small, unglamorous asset buy that quietly paid for itself many times over as a durable oncology cash-flow product
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Cell Therapeutics, Inc. (this deal) | 2005 | $70M | 74 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) | 2005 | $360M | 63 |
← Browse all deals · How we score deals
More: 2005 deals · Cephalon Inc. deals